In last trading session, Syros Pharmaceuticals Inc (NASDAQ:SYRS) saw 4.93 million shares changing hands with its beta currently measuring 1.34. Company’s recent per share price level of $0.27 trading at $0.02 or 6.62% at ring of the bell on the day assigns it a market valuation of $7.66M. That closing price of SYRS’s stock is at a discount of -2925.93% from its 52-week high price of $8.17 and is indicating a premium of 33.33% from its 52-week low price of $0.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 44.43 million shares which gives us an average trading volume of 7.81 million if we extend that period to 3-months.
For Syros Pharmaceuticals Inc (SYRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.50. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.71 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Upright in the green during last session for gaining 6.62%, in the last five days SYRS remained trading in the red while hitting it’s week-highest on Monday, 11/25/24 when the stock touched $0.27 price level, adding 9.67% to its value on the day. Syros Pharmaceuticals Inc’s shares saw a change of -96.57% in year-to-date performance and have moved -7.76% in past 5-day. Syros Pharmaceuticals Inc (NASDAQ:SYRS) showed a performance of -89.43% in past 30-days. Number of shares sold short was 4.77 million shares which calculate 1.38 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 98.2% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -1751.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1751.85% for stock’s current value.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
Statistics highlight that Syros Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -94.65% of value to its shares in past 6 months, showing an annual growth rate of 65.53% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -95.47% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 450k for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.16% during past 5 years.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
Insiders are in possession of 1.38% of company’s total shares while institution are holding 75.59 percent of that, with stock having share float percentage of 76.64%. Investors also watch the number of corporate investors in a company very closely, which is 75.59% institutions for Syros Pharmaceuticals Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 654.18 shares of worth $0.17 million or 2.44% of the total outstanding shares. The later fund manager was in possession of 255.42 shares on Jun 30, 2024 , making its stake of worth around $68325.0 in the company or a holder of 0.95% of company’s stock.
